New Weight-Loss Pill Foundayo Hits the Market

Lilly's once-daily medication promises 'greater flexibility' for adults struggling with obesity and weight-related conditions

Apr. 3, 2026 at 8:44am

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray photograph revealing the intricate internal structure of the human digestive system, conceptually representing the complex biological mechanisms involved in weight regulation and metabolism.A new weight-loss pill aims to offer adults struggling with obesity a more flexible treatment option, though potential side effects require careful medical supervision.Houston Today

The FDA has approved Foundayo, a new weight-loss pill developed by Lilly. Clinical trials showed adults taking the highest dose lost an average of 27.3 pounds, although the medication comes with potential side effects like thyroid tumors and gastrointestinal issues. Foundayo is the second obesity drug approved for Lilly, joining their previous medication Zepbound.

Why it matters

Obesity is a growing health crisis, with fewer than 1 in 10 people who could benefit from GLP-1 medications currently taking them. New treatment options like Foundayo that offer more flexibility in dosing and administration could help expand access and reduce stigma around seeking obesity treatment.

The details

Foundayo (orforglipron) is a once-daily, oral GLP-1 medication approved by the FDA for adults who are overweight or obese and have weight-related medical problems. In clinical trials, participants taking the highest dose lost an average of 27.3 pounds (12.4%). The drug is intended to be taken alongside a reduced-calorie diet and increased physical activity. However, Foundayo may cause serious side effects like thyroid tumors, and common side effects include gastrointestinal issues.

  • Foundayo will be available to ship to patients starting on April 6, 2026.

The players

Foundayo

A new once-daily weight-loss pill developed by Lilly that was recently approved by the FDA.

Lilly

A pharmaceutical company that developed Foundayo and received FDA approval for the new weight-loss medication.

Deborah Horn

The director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, who emphasized the importance of new treatment options for obesity.

David A. Ricks

The chair and CEO of Eli Lilly and Company, who commented on the need to improve access to GLP-1 medications for those living with obesity.

Got photos? Submit your photos here. ›

What they’re saying

“People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment.”

— Deborah Horn, Director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston

“Today, fewer than one in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity, or the belief that their condition isn't serious enough for treatment. We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications.”

— David A. Ricks, Chair and CEO of Eli Lilly and Company

What’s next

Lilly is also studying Foundayo as a potential treatment for other conditions like type 2 diabetes, sleep apnea, and hypertension.

The takeaway

The approval of Foundayo represents an important new treatment option for the growing number of adults struggling with obesity and weight-related health issues. However, the medication's potential side effects highlight the need for careful medical supervision and a comprehensive approach to weight management.